Fibromyalgia Treatment Market Size & Share 2025 – 2034

 Fibromyalgia Treatment Market Size

The global fibromyalgia treatment market was estimated at USD 2.3 billion in 2024. The market is expected to grow from USD 2.4 billion in 2025 to USD 3.4 billion in 2034, at a CAGR of 4.2% during the forecast period. The market growth for fibromyalgia treatments is driven by the rising understanding of its complex pathophysiological features, including neurochemical imbalances and central sensitization.

Additionally, the growing global burden of chronic musculoskeletal disorders has heightened the demand for specialized treatment approaches to relieve fibromyalgia symptoms. For instance, according to data from the National Institutes of Health (NIH), fibromyalgia affects approximately 10 million people in the U.S., highlighting the need for improved therapeutic options.
 

Newer diagnostic methods such as quantitative sensory testing and the development of biomarkers for chronic pain syndromes make early and accurate diagnoses improve. The use of technology, such as functional MRI and proteomic analysis, is central to identifying specific pain pathways and tailoring treatment strategies, boosting market growth. Further, the incorporation of AI-powered platforms and digital health technologies has enhanced symptom tracking and management, enabling more personalized care approaches.
 

In addition, the shift towards non-invasive treatments such as neuromodulation and biofeedback indicate a growing acceptance of holistic frameworks. Cross-industry collaboration among pharmaceutical companies, academic peers, and clinical practitioners has catalyzed the development of advanced therapeutics, changing the course of treatment approaches and outcomes.
 

The market encompasses pharmaceutical, non-pharmacological aimed at managing chronic pain, fatigue, and associated symptoms of fibromyalgia. It includes medications such as analgesics and antidepressants and alternative therapies.
 

Fibromyalgia Treatment Market Trends

• As the number of cases of fibromyalgia increases on a global scale, it has become one of the main drivers for the growth of the market. It is a debilitating illness characterized by chronic pain, fatigue, and cognitive difficulties that negatively impacts millions globally.
   
• The condition is often underdiagnosed, but awareness among health care professionals and patients is on the rise and will help support stronger diagnostic and treatment infrastructure.
   
• Data by the National Institutes of Health (NIH) suggests that fibromyalgia affects approximately 2% to 8% of the population worldwide, with higher prevalence among women. Chronic pain conditions such as fibromyalgia are currently some of the most common causes of disability according to the World Health Organization (WHO).
   
• Further, with the increasing concern over opioid misuse and dependence, the treatment paradigm is now changing due to the availability of non-opioid treatment anticonvulsants, antidepressants, cognitive behavioral therapy, and acupuncture.
   
• Moreover, increased healthcare spending and insurance coverage for chronic pain management further drive market growth. In 2023, the U.S. Centers for Medicare & Medicaid Services reported that expenditures on healthcare including chronic pain treatments exceeded USD 4.9 trillion or USD 14,570 per person, highlighting the attention given to quality-of-life issues for these individuals.
   
• Fibromyalgia’s multifactorial nature, involving central sensitization, sleep disturbance, and emotional dysregulation, underscores the demand for integrative approaches. Reports suggest around 50%-70% of fibromyalgia patients have at least one co-occurring mental health disorder, highlighting the need for psychological treatment.
   
• Alongside raising awareness, specific guidelines are being designed at the national level. For instance, in early 2024 the UK's National Institute for Health and Care Excellence (NICE) updated the treatment of fibromyalgia to include a broader application of patient and digital health technologies for better user assistance, active monitoring, and early intervention.
   
• Overall, because of changing clinical practices, emerging health policies, and active patients’ advocacy programs, the treatment market for fibromyalgia is expected to experience strong growth.
   

Trump Administration Tariffs

• The Trump administration's tariffs on Chinese imports, such as medical device components and pharmaceutical ingredients, might increase the costs for raw materials in drug manufacturing as well as in health monitoring tools, which may disrupt the fibromyalgia treatment market. These tariffs may interfere with the supply of affordable APIs (active pharmaceutical ingredients) which are essential components in manufacturing drugs such as pregabalin and milnacipran.
   
• Fibromyalgia treatment manufacturers who rely on Chinese suppliers may have no choice but to adopt new sourcing strategies from India, South Korea, and the EU, resulting in increased production costs and delays.
   
• Moreover, the increased costs for electronic sensors and communication modules might lead to a decline in the availability of telehealth and wearable devices used in pain management. In response, companies may start to reevaluate contract terms, overhaul their supply chains, and purchase more production equipment to lessen reliance on external tariff-controlled imports and sustain treatment continuity.
   

Fibromyalgia Treatment Market Analysis

In 2021, the global market was valued at USD 2.10 billion. The following year, it saw a slight increase to USD 2.16 billion, and by 2023, the market further climbed to USD 2.33 billion.
 

Based on the treatment type, the market is segmented into medication and therapy. The medication segment is divided into antidepressants, anticonvulsants, analgesics, muscle relaxants, and other medications. The medication segment dominated the market with USD 1.7 billion in 2024.
 

• Due to increased patients’ expectations towards pain, fatigue, and subsequent symptom management, demand is rising for pharmacological approaches which explains why the medication segment dominates the market. Key drug classes include antidepressants, anticonvulsants, and analgesic drugs that help patients enjoy a better quality of life.
   
• The growth in this segment is supported by the launch of new drugs and their reformulations, along with increased marketing authorizations of existing ones, such as pregabalin which was one of the first FDA-approved drugs specifically for fibromyalgia.
   
• Moreover, greater emphasis on combination therapies and personalized medicine technology drives further innovation responding to unfulfilled needs and fueling market development within the medication segment.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on gender, the fibromyalgia treatment market is divided into male and female. The female segment accounted for significant market share of 80.5% in 2024.
 

• The female segment represents a significant share of the market, as the condition disproportionately affects women. As reported by NCBI, fibromyalgia syndrome has a high female predominance, which comprises 80%–96% of the cases. These differences have been explained based on some hormonal factors, greater pain perception, and variations in the functions of the nervous system.
   
• The higher prevalence among women has driven focused investigations targeted toward the development of gender-sensitive diagnostic techniques and treatment options. For example, certain treatment strategies such as hormone therapy and cognitive behavioral therapy are being developed to mitigate the effects of fibromyalgia in women.
   
• Additionally, increased advocacy and health campaigns targeting women positively increase the willingness of this population to seek timely diagnosis and effective treatment options.
   

Based on end use, the fibromyalgia treatment market is divided into hospitals, specialty clinics, and other end users. The hospital and clinics segment dominated the market in 2024 and is expected to reach 1.8 billion by 2034.
 

• Hospitals offer a wide range of services which include initial assessment, prescribing medications, and treating the patient using various medical disciplines. Integration with nutrition, physiotherapy, rheumatology, clinical psychology, and specialized pain management offers fibromyalgia patients multidisciplinary care to achieve better prognosis.
   
• In addition, these patients are expected to benefit from advanced methods of diagnosis and treatment available in the management setting of the hospital. Additionally, hospitals often participate in clinical trials, contributing to the development of new therapies.
   
• With the growing awareness and more people being diagnosed with fibromyalgia, there is an increasing need for treatment in a hospital setting which will accelerate the growth of the market.
   

The North America fibromyalgia treatment market held the largest market share of 43.3% in 2024 in the global market, and it is anticipated to expand at a 4.1% CAGR over the forecast period. The U.S. market was valued at USD 907.2 million in 2024.
 

• The U.S. leads the global market due to its quality healthcare system, high disease prevalence, and extensive pharmaceutical industry.
   
• FDA-approved drugs such as duloxetine, milnacipran, and pregabalin dominate the prescription landscape. Patients are further motivated to seek treatment due to awareness programs and insurance coverage.
   
• Emerging trends include the use of telemedicine for diagnosis as well as the shifts toward a more personal approach to medicine.
   
• Clinical research dedicated to new therapy approaches includes non-pharmaceutical options such as cognitive behavioral therapy and lifestyle changes. However, increasing spending on healthcare remains a problem for wider access.
   

The Germany fibromyalgia treatment market is experiencing robust growth in Europe market.
 

• In Germany, the market is characterized by an integrated approach that blends traditional medicinal approaches with physiotherapy, psychotherapy, and other complementary treatments.
   
• The German healthcare system provides access to treatment through universal health insurance which leads to a wide range of treatment options for fibromyalgia patients. The system is supported by the focus given to patient-oriented treatment and the demand for tailored services.
   

The Asia Pacific fibromyalgia treatment market is witnessing substantial growth of 4.5% during the analysis period.
 

• Awareness of fibromyalgia, its symptoms, and its treatment options in the Chinese treatment market is comparatively lower than in western countries. The condition is treated with acupuncture and herbal medicine as well as with modern drugs. Traditional Chinese Medicine's application is broad, with acupuncture being a widely practiced subfield.
   
• Progress is being made in the management of chronic pain at the governmental level. There is increased focus on diagnostic and therapeutic setting frameworks. Emerging trends include studying the lifestyle influences as well as genetic factors on the population adjusted for the Chinese heritage.
   
• Additionally, disparities in advanced therapies due to inadequate insurance coverage and gaps in standardized protocols for treatment continue to burden the system. There is an increased predominance of stress disorders because of urbanization and other factors.
   

The Brazil fibromyalgia treatment market is experiencing robust growth in Latin America market.
 

• Acupuncture, physical therapy, and pharmaceutical treatments enable Brazil to dominate the market in Latin America. Brazil's mixed healthcare system enables the provision of diverse treatment options.
   
• While there is a high demand for pain-suppressing drugs, such as antidepressant drugs, access to specialized care remains limited in rural regions.
   
• With expansion in the understanding of fibromyalgia, there is growing interest regarding its alternative treatments, which has expanded the holistic therapy market parallel to the traditional medicine market.
   

The Saudi Arabia fibromyalgia treatment market is witnessing substantial growth in Middle East and Africa during the analysis period.
 

• The healthcare system in Saudi Arabia is continuously being developed under Vision 2030, which is impacting the market in the country. Enhanced spending on healthcare has refined the country’s diagnostic potential.
   
• The treatment options consist mainly of pharmacological treatments, such as pregabalin and pain management drugs, along with physical therapy and psychosocial support.
   
• Further, limitations include a very small number of specialized pain clinics and high costs of advanced treatment options. There is an increasing attempt to include holistic and lifestyle modification efforts.
   

Fibromyalgia Treatment Market Share

The top 5 companies in the market, such as Pfizer, Eli Lilly and Company, AbbVie, Teva Pharmaceutical, and Novartis, account for approximately 65% of the market share. These firms maintain their leadership through robust research and development pipelines, innovative drug formulations, and expansion into non-pharmacological therapies. Companies such as AbbVie and Eli Lilly continue to invest in next-generation neuromodulators and CNS-targeted therapies, while Teva and Pfizer are advancing extended-release and low-dose solutions to improve efficacy and minimize side effects.
 

Institutions such as Mayo Clinic, UT Health Austin, and The General Hospital Corporation are pioneering multidisciplinary treatment models, integrating pharmacologic and behavioral care. Meanwhile, players such as Sun Pharma, Viatris, and Zydus are expanding access through affordable generics and biosimilars. With growing interest in digital therapeutics and AI-assisted symptom tracking, the market is seeing heightened competition and broader therapeutic innovation.
 

Fibromyalgia Treatment Market Companies

Major players operating in the fibromyalgia treatment industry are:

• Abbott Laboratories
• AbbVie
• Amneal Pharmaceuticals
• AstraZeneca
• Colorado Fibromyalgia Center
• Eli Lilly and Company
• Lupin
• Mayo Clinic
• Novartis
• Pfizer
• Sun Pharmaceutical
• Teva Pharmaceutical
• The General Hospital Corporation
• UT Health Austin
• Viatris
• Zydus Lifesciences
   
• AbbVie markets Savella (milnacipran HCl), a selective serotonin and norepinephrine reuptake inhibitor (SNRI) approved specifically for fibromyalgia. Savella helps manage widespread pain and fatigue, targeting central nervous system imbalances. AbbVie supports this therapy with educational resources and digital tools, promoting comprehensive, evidence-based care for fibromyalgia patients.
   
• Pfizer stands out in the fibromyalgia treatment market with its well-established product Lyrica (pregabalin), a leading FDA-approved treatment for fibromyalgia. Pfizer’s commitment to chronic pain management is reflected in its continued investment in post-market studies, patient support programs, and digital health tools that enhance treatment adherence and real-time symptom monitoring, improving quality of life for patients.
   
• Eli Lilly and Company offers a strong presence through Cymbalta (duloxetine), one of the first antidepressants approved for fibromyalgia. Eli Lilly leverages its neuroscience expertise to develop therapies targeting central sensitization. The company supports integrated care models through physician education and real-world data initiatives that optimize treatment outcomes.
   

Fibromyalgia Treatment Industry News

• In January 2023, Amneal Pharmaceuticals and Orion Corporation signed a long-term license agreement to market Amneal's complex generic medicines, including potential fibromyalgia treatments, across Europe, Australia, and New Zealand, expanding access to advanced pain management therapies.
   
• In May 2022, Lupin received FDA approval for its Pregabalin Capsules, a generic version of Lyrica. This approval enhances access to affordable treatment options for fibromyalgia, supporting patients with chronic pain and related conditions.
   
• In February 2022, Zydus received final FDA approval to market Nortriptyline Hydrochloride Capsules USP in the U.S. While primarily used for depression, Nortriptyline is also prescribed off-label to manage fibromyalgia symptoms, supporting Zydus’s presence in the market.
   

The fibromyalgia treatment market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Medication
  • Antidepressants
  • Anticonvulsants
  • Analgesics
  • Muscle relaxants
  • Other medications
• Therapy
  • Physical therapy
  • Occupational therapy
  • Other therapies

Market, By Gender

• Male
• Female

Market, By End Use

• Hospitals
• Specialty clinics 
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE